Chasing Clot: Thrombophilic States and the Interventionalist

Journal of Vascular and Interventional Radiology

Volumn 20, Issue 11, 2009, Pages 1403-1416

  Valji, Karim ^a   Linenberger, Michael ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN; APC; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5 LEIDEN; ESTROGEN; ORAL CONTRACEPTIVE AGENT; PROTHROMBIN; WARFARIN;

ANTIPHOSPHOLIPID SYNDROME; BLOOD CLOTTING; DISEASE ASSOCIATION; ESTROGEN THERAPY; GENE MUTATION; HEPARIN INDUCED THROMBOCYTOPENIA; HORMONE SUBSTITUTION; HUMAN; HYPERHOMOCYSTEINEMIA; IDIOPATHIC DISEASE; NEOPLASM; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; RECANALIZATION; REVIEW; RISK ASSESSMENT; THROMBOPHILIA; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

DIAGNOSIS, DIFFERENTIAL; HUMANS; RADIOGRAPHY, INTERVENTIONAL; THROMBOPHILIA; THROMBOSIS;

EID: 70350503085     PISSN: 10510443     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jvir.2009.08.015     Document Type: Review

References (138)

1. Perler B.A. Hypercoagulability and the hypercoagulability syndromes. AJR Am J Roentgenol 164 (1995) 559-564
2. Heijboer H., Brandjes D.P., Buller H.R., Sturk A., and ten Cate J.W. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep venous thrombosis. N Engl J Med 323 (1990) 1512-1516
3. Gladson C.L., Scharrer I., Hach V., Beck K.H., and Griffin J.H. The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis. Thromb Haemost 59 (1988) 18-22
4. Dahlbäck B. Advances in understanding pathogenic mechanisms of thrombophilic disorders. Blood 112 (2008) 19-27
5. Bick R.L. Hereditary and acquired thrombophilic disorders. Clin Appl Thromb Hemost 12 (2006) 125-135
6. Martinelli I., Battaglioli T., Bucciarelli P., Passamonti S.M., and Mannucci P.M. Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities. Circulation 110 (2004) 566-570
7. Glueck C.J., Wang P., Hutchins R., Petersen M.R., and Golnik K. Ocular vascular thrombotic events: central retinal vein and central retinal artery occlusions. Clin Appl Thromb Hemost 14 (2008) 286-294
8. Ye Z., Liu E.H.C., Higgins J.P.T., et al. Seven haemostatic gene polymorphisms in coronary disease: meta-analysis of 66 155 cases and 91 307 controls. Lancet 367 (2006) 651-658
9. Chan M.Y., Andreotti F., and Becker R.C. Hypercoagulable states in cardiovascular disease. Circulation 118 (2008) 2286-2287
10. Boekholdt S.M., and Kramer M.H.H. Arterial thrombosis and the role of thrombophilia. Semin Thromb Hemost 33 (2007) 588-596
11. Middeldorp S., and van Hylckama Vlieg A. Does thrombophilia testing help in the clinical management of patients?. Br J Haematol 143 (2008) 321-335
12. Middeldorp S., and Levi M. Thrombophilia: an update. Semin Thromb Hemost 33 (2007) 563-572
13. Simioni P., Tormene D., Spiezia L., et al. Inherited thrombophilia and venous thromboembolism. Semin Thromb Hemost 32 (2006) 700-708
14. Seligsohn U., and Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 344 (2001) 1222-1231
15. Whitlatch N.L., and Ortel T.L. Thrombophilias: when should we test and how does it help?. Semin Respir Crit Care Med 29 (2008) 25-39
16. Dahlbäck B. Blood coagulation and its regulation by anticoagulant pathways: genetic pathogenesis of bleeding and thrombotic diseases. J Intern Med 257 (2005) 209-233
17. Furie B., and Furie B.C. Mechanisms of thrombus formation. New Engl J Med 359 (2008) 938-949
18. Rijken D.C., and Lijnen H.R. New insights into the molecular mechanisms of the fibrinolytic system. J Thromb Haemost 7 (2009) 4-13
19. Dahlbäck B., Carlsson M., and Svensson P.J. Familial thrombophilia due to previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci U S A 90 (1993) 1004-1006
20. Bertina R.M., Koeleman B.P., Koster T., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 369 (1994) 64-67
21. Rosendorff A., and Dorfman D.M. Activated protein C resistance and factor V Leiden: a review. Arch Pathol Lab Med 131 (2007) 866-871
22. Christiansen S.C., Cannegieter S.C., Koster T., Vandenbroucke J.P., and Rosendaal F.R. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA 293 (2005) 2352-2361
23. Cushman M. Epidemiology and risk factors for venous thrombosis. Semin Hematol 44 (2007) 62-69
24. Ridker P.M., Miletich J.P., Henneckens C.H., and Buring J.E. Ethnic distribution of factor V Leiden in 4047 men and women. JAMA 277 (1997) 1305-1307
25. Salomon O., Steinberg D.M., Zivelin A., et al. Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. Arterioscler Thromb Vasc Biol 19 (1999) 511-518
26. Rosendaal F.R. Venous thrombosis: a multicausal disease. Lancet 353 (1999) 1167-1173
27. Emmerich J., Rosendaal F.R., Cattaneo M., et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism: pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled Analysis in Venous Thromboembolism. Thromb Haemost 86 (2001) 809-816
28. Lijfering W.M., Brouwer J.L., Veeger N.J., et al. Selective testing for thrombophilia in patients with first venous thrombosis. Results from a retrospective family cohort study on absolute risk for currently known thrombophilic defects in 2479 relatives. Blood 113 (2009) 5314-5322
29. Robertson L., Wu O., Langhorne P., et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol 132 (2006) 171-196
30. Gerhardt A., Scharf R.E., and Zotz R.B. Effect of hemostatic risk factors on the individual probability of thrombosis during pregnancy and the puerperium. Thromb Haemost 90 (2003) 77-85
31. Ridker P.M., Hennekens C.H., Lindpainter K., Stampfer M.J., Eisenberg P.R., and Miletich J.P. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke and venous thrombosis in apparently healthy men. N Eng J Med 332 (1995) 912-917
32. Cushman M., Rosendaal F.R., Psaty B.M., et al. Factor V Leiden is not a risk factor for arterial vascular disease in the elderly. Results from the Cardiovascular Health Study. Thromb Haemost 79 (1998) 912-915
33. Juul K., Tybjaerg-Hansen A., Steffensen R., Kofoed S., Jensen G., and Nordestgaard B.G. Factor V Leiden: the Copenhagen City Heart Study and 2 meta-analyses. Blood 100 (2002) 3-10
34. Gomez F., Rodriguez A., Rivas J., Baez J.M., Romero S., and Marina D. Mesenteric arterial thrombosis due to activated protein C resistance (factor V Leiden). Surgery 128 (2000) 494-496
35. vanBuren S.F., Heit J.A., Panneton J.M., and Donohue J.H. Iliac arterial thrombosis after inguinal hernia repair. Mayo Clin Proc 77 (2002) 1361-1363
36. Wahlander K., Larson G., Lindahl T.L., et al. Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery. Thromb Haemost 87 (2002) 580-585
37. Vossen C.Y., Walker I.D., Svensson P., et al. Recurrence rate after a first venous thrombosis in patients with familial thrombophilia. Arterioscler Thromb Vasc Biol 25 (2005) 1992-1997
38. Baglin T., Luddington R., Brown K., and Baglin C.L. Incidence of recurrent thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 362 (2003) 523-526
39. Ho W.K., Hankey G.J., Quinlan D.J., and Eikelboom J.W. Risk of recurrent venous thromboembolism in patients with common thrombophilia. Arch Intern Med 166 (2006) 729-736
40. Vinazzer H. Hereditary and acquired antithrombin deficiency. Semin Thromb Hemost 25 (1999) 257-263
41. Kuhle S., Lane D.A., Jochmanns K., et al. Homozygous antithrombin deficiency type II (99 Leu to Phe mutation) and childhood thromboembolism. Thromb Haemost 86 (2001) 1007-1011
42. Maclean P.S., and Tait R.C. Hereditary and acquired antithrombin deficiency: epidemiology, pathogenesis and treatment options. Drugs 67 (2007) 1429-1440
43. Tiede A., Tait R.C., Shaffer D.W., et al. Antithrombin alfa in hereditary antithrombin deficient patients: a phase 3 study of prophylactic intravenous administration in high risk situations. Thromb Haemost 99 (2008) 616-622
44. Tait R.C., Walker I.D., Reitsma P.H., et al. Prevalence of protein C deficiency in the healthy population. Thromb Haemost 73 (1995) 87-93
45. Koster T., Rosendaal F.R., Briet E., et al. Protein C deficiency in a controlled series of unselected outpatients: an infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood 85 (1995) 2756-2761
46. Brouwer J.L., Lijfering W.M., Ten Kate M.K., et al. High long-term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C or antithrombin. Thromb Haemost 101 (2009) 93-99
47. Mahmoodi B.K., Brouwer J.L., Veeger N.J., and van der Meer J. Hereditary deficiency of protein C or protein S confers increased risk of arterial thromboembolic events at a young age: results from a large family cohort study. Circulation 118 (2008) 1659-1667
48. van Vlijmen E.F., Brouwer J.L., Veeger N.J., Eskes T.K., de Graeff P.A., and van der Meer J. Oral contraceptives and the absolute risk of venous thromboembolism in women with single or multiple thrombophilic defects. Arch Intern Med 167 (2007) 282-289
49. Zoller B., Garcia de Frutos P., and Dahlback B. Evaluation of the relationship between protein S and C4b-binding protein isoforms in hereditary protein S deficiency demonstrating type I and type III deficiencies to be phenotypic variants of the same genetic disease. Blood 85 (1995) 3524-3531
50. ten Kate M.K., and van der Meer J. Protein S deficiency: a clinical perspective. Haemophilia 14 (2008) 1222-1228
51. Lijfering W.M., Mulder R., ten Kate M.K., Veeger N.J., Mulder A.B., and van der Meer J. Clinical relevance of decreased free protein S levels: results from a retrospective family cohort study involving 1143 relatives. Blood 113 (2009) 1225-1230
52. Lijfering W.M., Sprenger H.G., Georg R.R., van der Meulen P.A., and van der Meer J. Relationship between progression to AIDS and thrombophilic abnormalities in HIV infection. Clin Chem 54 (2008) 1226-1233
53. Tsai A.W., Cushman M., Rosamond W.D., et al. Coagulation factors, inflammation markers, and venous thromboembolism etiology (LITE). Am J Med 113 (2002) 636-642
54. O'Donnell J., Tuddenham E.G., Manning R., Kemball-Cook G., Johnson D., and Laffan M. High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to acute phase reaction. Thromb Haemost 77 (1997) 825-828
55. Kamphuisen P.W., Eikenboom J.C., Rosendaal F.R., et al. High factor VIII antigen levels increase the risk of venous thrombosis but are not associated with polymorphisms in the von Willebrand factor and factor VIII gene. Br J Haematol 115 (2001) 156-158
56. Bank I., Libourel E.J., Middeldorp S., et al. Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis. J Thromb Haemost 3 (2005) 79-84
57. Kyrle P.A., Minar E., Hirschl M., et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 343 (2000) 1968-1969
58. Kyrle P.A., Minar E., Bialonczyk C., Hirschl M., Weltermann A., and Eichinger S. The risk of recurrent venous thromboembolism in men and women. N Engl J Med 350 (2004) 2558-2563
59. Cosmi B., Legnani C., Cini M., Favaretto E., and Palareti G. D-dimer and factor VIII are independent risk factors for recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis. Thromb Res 122 (2008) 610-617
60. Shrivastava S., Ridker P.M., Glynn R.J., et al. D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism. J Thromb Haemost 4 (2006) 1208-1214
61. van Hylckama Vlieg A., van der Linden I.K., Bertina R.M., and Rosendaal F.R. High levels of factor IX increase the risk of venous thromboembosis. Blood 95 (2000) 3678-3682
62. Meijers J.C., Tekelenburg W.L.H., Bouma B.N., Bertina R.M., and Rosendaal F.R. High levels of coagulation factor XI as a risk factor for venous thrombosis. N Engl J Med 342 (2000) 696-701
63. Doggen C.J., Rosendaal F.R., and Meijers J.C. Levels of intrinsic coagulation factors and the risk of myocardial infarction among men: opposite and synergistic effects of factors XI and XII. Blood 108 (2006) 4045-4051
64. Cortese C., and Motti C. MTHFR gene polymorphism, homocysteine and cardiovascular disease. Public Health Nutr 4 (2001) 493-497
65. Naess I.A., Christiansen S.C., Romundstad P.R., et al. Prospective study of homocysteine and MTHFR 677TT genotype and risk for venous thrombosis in a general population - results from the HUNT 2 study. Br J Haematol 141 (2008) 529-535
66. Frederiksen J., Juul K., Grande P., et al. Methylenetetrahydrofolate reductase polymorphism (C677TT), hyperhomocysteinemia, and risk of ischemic cardiovascular disease and venous thromboembolism: prospective and case-control studies from the Copenhagen City Heart Study. Blood 104 (2004) 3046-3051
67. Tsai A.W., Cushman M., Tsai M.Y., et al. Serum homocysteine, thermolabile variant of methylene tetrahydrofolate reductase (MTHFR), and venous thromboembolism: Longitudinal Investigation of Thromboembolism Etiology (LITE). Am J Hematol 72 (2003) 192-200
68. Bezemer I.D., Doggen C.J., Vos H.L., and Rosendaal F.R. No association between the common MTHFR 677C → T polymorphism and venous thrombosis: results from the MEGA study. Arch Intern Med 167 (2007) 497-501
69. Alhenc-Gelas M., Arnaud E., Nicaud V., et al. Venous thromboembolic disease and the prothrombin, methylene tetrahydrofolate reductase and factor V genes. Thromb Haemost 81 (1999) 506-510
70. Ray J.G., Kearon C., Yi Q., Sheridan P., Lonn E., and Heart Outcomes Prevention Evaluation 2 (HOPE-2) Investigators. Homocysteine-lowering therapy and risk for venous thromboembolism: a randomized trial. Ann Intern Med 146 (2007) 761-767
71. den Heijer M., Willems H.P., Blom H.J., et al. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: a randomized, placebo-controlled, double-blind trial. Blood 109 (2007) 139-144
72. Lonn E., Yusuf S., Arnold M.J., et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354 (2006) 1567-1577
73. Bonaa K.H., Njolstad I., Ueland P.M., et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354 (2006) 1578-1588
74. von Depka M., Nowak-Gottl U., Eisert R., et al. Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. Blood 96 (2000) 3364-3368
75. Coulam C.B., Wallis D., Weinstein J., et al. Comparison of thrombophilic gene mutations among patients experiencing recurrent miscarriage and deep vein thrombosis. Am J Reprod Immunol 60 (2008) 426-431
76. Meltzer M.E., Lisman T., Doggen C.J.M., et al. Synergistic effects of hypofibrinolysis and genetic and acquired risk factors on the risk of a first venous thrombosis. PloS Med 5 (2008) e97
77. Meltzer M.E., Doggen C.J., de Groot P.M., et al. Reduced plasma fibrinolytic capacity as a potential risk factor for a first myocardial infarction in young men. Br J Haematol 145 (2009) 121-127
78. Guimarães A.H.C., de Bruijne E.L.E., Lisman T., et al. Hypofibrinolysis is a risk factor for arterial thrombosis at a young age. Br J Haematol 145 (2009) 115-120
79. Frenkel E.P., and Mammen E.F. Sticky platelet syndrome and thrombocythemia. Hematol Oncol Clin North Am 17 (2003) 63-83
80. Bick R.L., and Hoppensteadt D. Recurrent miscarriages syndrome and infertility due to blood coagulation protein/platelet defects: a review and update. Clin Appl Thromb Hemost 11 (2005) 1-13
81. Fateh-Moghadam S., Htun P., Tomandl B., et al. Hyperresponsiveness of platelets in ischemic stroke. Thromb Haemost 97 (2007) 974-978
82. Kubisz P., Ivankov J., Holly P., Stasko J.N., and Musiał J. The glycoprotein IIIa PL A1/A2 polymorphism-a defect responsible for the sticky platelet syndrome?. Clin Appl Thromb Hemost 12 (2006) 117-119
83. Miyakis S. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4 (2006) 295-306
84. Baker W.F., and Bick R.L. The clinical spectrum of antiphospholipid syndrome. Hematol Oncol Clin North Am 22 (2008) 33-52
85. Cervera R., Piette J.C., Font L., et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1000 patients. Arthritis Rheum 46 (2002) 1019-1027
86. Pierangeli S.S., Chen P.P., Raschi E., et al. Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms. Semin Thromb Hemost 34 (2008) 236-250
87. Lim W., Crowther M.A., and Eikelboom J.W. Management of antiphospholipid antibody syndrome: a systematic review. JAMA 295 (2006) 1050-1057
88. Erkan D., and Lockshin M.D. New approaches for managing antiphospholipid syndrome. Nat Clin Pract Rheumatol 5 (2009) 160-170
89. Khorana A.A. Malignancy, thrombosis and Trousseau: the case for an eponym. J Thromb Haemostasis 1 (2003) 2463-2465
90. Heit J.A., Silverstein M.D., Mohr D.N., Petterson T.M., O'Fallon W.M., and Melton III L.J. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 160 (2000) 809-815
91. Lee A.Y.Y., and Levine M.N. Venous thromboembolism and cancer: risks and outcomes. Circulation 107 (2003) 1-17
92. Carrier M., LeGal G., Wells P.S., Fergusson D., Ramsay T., and Rodger M.A. Systematic review: the Trousseau syndrome revisited: should we screen extensively for cancer in patients with venous thromboembolism?. Ann Intern Med 149 (2008) 323-333
93. Linenberger M.L., and Wittkowsky A.K. Thromboembolic complications of malignancy. Part 1: risks. Oncology (Williston Park) 19 (2005) 853-861
94. Valji K. Vascular and Interventional Radiology. 2nd ed. (2006), Saunders/Elsevier, Philadelphia 56
95. Gouin-Thibault I., Achkar A., and Samanam M.M. The thrombophilic state in cancer patients. Acta Haematol 106 (2001) 33-42
96. Wagman L.D., Baird M.F., Bennett C.L., et al. Venous thromboembolic disease. NCCN. Clinical practice guidelines in oncology. J Natl Compr Canc Netw 6 (2008) 716-753
97. Tefferi A., and Elliott M. Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F. Semin Thromb Hemost 33 (2007) 313-320
98. Ziakas P.D., Poulou L.S., and Pomoni A. Thrombosis in paroxysmal nocturnal hemoglobinuria at a glance: a clinical review. Curr Vasc Pharmacol 6 (2008) 347-353
99. Tefferi A. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy. Am J Hematol 83 (2008) 491-497
100. Baldwin Z.K., Spitzer A.L., Ng V.L., and Harken A.H. Contemporary standards for the diagnosis and treatment of heparin-induced thrombocytopenia (HIT). Surgery 143 (2008) 305-312
101. Keeling D., Davidson S., and Watson H. The management of heparin-induced thrombocytopenia. Br Soc Hematol 133 (2006) 259-269
102. Chong B.H., and Isaacs A. Heparin-induced thrombocytopenia: what clinicians need to know. Thromb Haemost 101 (2009) 279-283
103. Hong A.P., Cook D.J., Sigouin C.S., and Warkentin T.E. Central venous catheters and upper-extremity deep-vein thrombosis complicating immune heparin-induced thrombocytopenia. Blood 101 (2003) 3049-3051
104. Hopkins C.K., and Goldfinger D. Platelet transfusions in heparin-induced thrombocytopenia: a report of four cases and review of the literature. Transfusion 48 (2008) 2128-2132
105. vanVlijmen E.F., Brouwer J.L., Veeger N.J., Eskes T.K., de Graeff P.A., and van der Meer J. Oral contraceptives and the absolute risk of venous thromboembolism in women with single or multiple thrombophilic defects: results from a retrospective family cohort study. Arch Intern Med 167 (2007) 282-289
106. Folkeringa N., Brouwer J.L., Korteweg F.J., Veeger N.J., Erwich J.J., and van der Meer J. High risk of pregnancy-related venous thromboembolism in women with multiple thrombophilic defects. Br J Haematol 138 (2007) 110-116
107. Stella C.L., and Sibai B.M. Thrombophilia and adverse maternal-perinatal outcome. Clin Obstet Gynecol 49 (2006) 850-860
108. Linenberger M.L. Catheter-related thrombosis: risks, diagnosis, and management. J Natl Compr Canc Netw 4 (2006) 889-901
109. Koster T., Rosendaal F.R., deRonde H., et al. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 342 (1993) 1503-1506
110. Lindhoff-Last E., and Luxembourg B. Evidence-based indications for thrombophilia screening. Vasa 37 (2008) 19-30
111. Cho Y.P., Kwon T.W., Ahn J.H., et al. Protein C and/or S deficiency presenting as peripheral arterial insufficiency. Br J Radiol 78 (2005) 601-605
112. Levy P.J., Hornung C.A., Haynes J.L., and Rush D.S. Lower extremity ischemia in adults younger than forty years of age: a community wide survey of premature atherosclerotic arterial disease. J Vasc Surg 19 (1994) 873-881
113. Donaldson M.C., Belkin M., Whittemore A.D., Mannick J.A., Longtine J.A., and Dorfman D.M. Impact of activated protein C resistance on general vascular surgical patients. J Vasc Surg 25 (1997) 1054-1060
114. Vig S., Chitolie A., Bevan D., Dormandy J., Thompson M.M., and Halliday A. The prevalence of thrombophilia in patients with symptomatic peripheral vascular disease. Br J Surg 93 (2006) 577-581
115. Sofi F., Lari B., Rogolino A., et al. Thrombophilic risk factors for symptomatic peripheral arterial disease. J Vasc Surg 41 (2005) 255-260
116. Knoll G.A., Wells P.S., Young D., et al. Thrombophilia and the risk for hemodialysis vascular access thrombosis. J Am Soc Nephrol 16 (2005) 1108-1114
117. O'Shea S.I., Lawson J.H., Reddan D., Murphy M., and Ortel T.L. Hypercoagulable states and antithrombotic strategies in recurrent vascular access site thrombosis. J Vasc Surg 38 (2003) 541-548
118. Ludwig D.J., Hauptmann E., Rosoff L., and Neuzil D. Mesenteric and portal vein thrombosis in a young patient with protein S deficiency treated with urokinase via the superior mesenteric artery. J Vasc Surg 30 (1999) 551-554
119. Rhee R.Y., Gloviczki P., Mendonca C.T., et al. Mesenteric venous thrombosis: still a lethal disease in the 1990s. J Vasc Surg 20 (1994) 688-697
120. Lussana F., Dentali F., Ageno W., and Kamphuisen P.W. Venous thrombosis at unusual sites and the role of thrombophilia. Semin Thromb Hemost 33 (2007) 582-587
121. Glueck C.J., Munjal J., Aregawi D., et al. Thrombophilia-hypofibrinolysis and atherothrombotic cardiovascular disease < or = age 45 years. Transl Res 150 (2007) 93-100
122. Kim H.S., Patra A., Khan J., Arepally A., and Streiff M.B. Transhepatic catheter-directed thrombectomy and thrombolysis of acute superior mesenteric venous thrombosis. J Vasc Interv Radiol 16 (2005) 1685-1691
123. Protack C.D., Bakken A.M., Patel N., Saad W.E., Waldman D.L., and Davies M.G. Long-term outcomes of catheter-directed thrombolysis for lower extremity deep venous thrombosis without prophylactic inferior vena cava filter placement. J Vasc Surg 45 (2007) 992-997
124. Cho Y.P., Jang H.J., Lee D.H., et al. Deep venous thrombosis associated with protein C and/or S deficiency: management with catheter directed thrombolysis. Br J Radiol 76 (2003) 380-394
125. Angle J.F., Matsumoto A.H., Al Shammari M., Hagspiel K.D., Spinosa D.J., and Humphries J.E. Transcatheter regional urokinase therapy in the management of inferior vena cava thrombosis. J Vasc Interv Radiol 9 (1998) 917-925
126. Valji K. Evolving strategies for thrombolytic therapy of peripheral vascular occlusions. J Vasc Interv Radiol 11 (2000) 411-420
127. Semba C.P., Bakal C.W., Calis K.A., et al. Alteplase as an alternative to urokinase. Advisory Panel on Catheter-Directed Thrombolytic Therapy. J Vasc Interv Radiol 11 (2000) 279-287
128. Benenati J., Shlansky-Goldberg R., Meglin A., and Seidl E. Consultants from the Reteplase and Abciximab for Peripheral Vascular Interventions Conference. Thrombolytic and antiplatelet therapy in peripheral vascular disease with use of reteplase and/or abciximab. The SCVIR Consultants' Conference. J Vasc Interv Radiol 12 (2001) 795-805
129. Katzen B.T., Ardid M.I., MacLean A.A., et al. Bivalirudin as an anticoagulation agent: safety and efficacy in peripheral interventions. J Vasc Interv Radiol 16 (2005) 1183-1187
130. Duda S., Tepe G., Luz O., et al. Peripheral artery occlusion: treatment with abciximab plus urokinase versus urokinase alone - a randomized pilot trial (the PROMPT study). Radiology 221 (2001) 689-696
131. Ouriel K., Castaneda F., McNamara T., et al. Reteplase monotherapy and reteplase/abciximab combination therapy in peripheral arterial occlusive disease: results from the RELAX trial. J Vasc Interv Radiol 15 (2004) 229-238
132. Tepe G., Hopfenzitz C., Dietz K., et al. Peripheral arteries: treatment with antibodies of platelet receptors and reteplase for thrombolysis - APART trial. Radiology 239 (2006) 892-900
133. Wu O., Robertson L., Twaddle S., et al. Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol Assess 10 (2006) 1-110
134. Sobel M., and Verhaeghe R. Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 Suppl (2008) 815S-843S
135. Kearon C., Kahn S.R., Agnelli G., Goldhaber S., Raskob G.E., and Comerota A.J. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 Suppl (2008) 454S-545S
136. Agnelli G., and Becattini C. Treatment of DVT: how long is enough and how do you predict recurrence. J Thromb Thrombolysis 25 (2008) 37-44
137. Prandoni P., Prins M.H., Lensing A.W.A., et al. Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. Ann Intern Med 150 (2009) 577-585
138. Verhovsek M., Douketis J.D., Yi Q., et al. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med 149 (2008) 481-490